Cutaneous T-Cell Lymphoma (CTCL)
Symptoms, Doctors, Treatments, Advances & More

Cutaneous T-Cell Lymphoma (CTCL) Overview

Save information for later
Sign Up

Learn About Cutaneous T-Cell Lymphoma (CTCL)

What is the definition of Cutaneous T-Cell Lymphoma (CTCL)?
Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by an abnormal accumulation of cancerous T-cells (a type of white blood cells) in the skin resulting in an itchy, red rash that can thicken or form a tumor. CTCLs belong to a larger group of disorders known asnon-Hodgkin's lymphomas. The most common types are mycosis fungoides and Sézary syndrome. In some cases, cancerous T-cells may spread to the lymph nodes and eventually to other body tissues and organs, potentially resulting in serious complications. The specific signs and symptoms vary from person to person. The exact cause of these conditions is unknown.
What are the alternative names for Cutaneous T-Cell Lymphoma (CTCL)?
  • Cutaneous T-cell lymphoma
  • CTCL
Who are the top Cutaneous T-Cell Lymphoma (CTCL) Local Doctors?
Larisa Geskin
Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Larisa Geskin
Oncology
Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Larisa Geskin
Oncology

CUIMC/Herbert Irving Pavilion

161 Fort Washington Ave, 
New York, NY 
347-508-2906
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Larisa Geskin is an Oncologist in New York, New York. Dr. Geskin is rated as an Elite provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). Her top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Sezary Syndrome.

Joan Guitart
Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Joan Guitart
Dermatology
Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Joan Guitart
Dermatology
676 N St Clair St Ste 1600, Arkes Pavilion, 
Chicago, IL 
312-695-8106
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joan Guitart is a Dermatologist in Chicago, Illinois. Dr. Guitart has been practicing medicine for over 43 years and is rated as an Elite provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, T-Cell Lymphoma, and Lymphomatoid Papulosis.

 
 
 
 
Learn about our expert tiers
Learn More
Alain H. Rook
Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Alain H. Rook
Dermatology
Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Alain H. Rook
Dermatology

Penn Dermatology Perelman

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
215-662-2737
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alain Rook is a Dermatologist in Philadelphia, Pennsylvania. Dr. Rook is rated as an Elite provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome. Dr. Rook is currently accepting new patients.

View All Doctors
What are the latest Cutaneous T-Cell Lymphoma (CTCL) Clinical Trials?
A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas
A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas
Who is this study for: Patients with Lymphoma
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Cyclophosphamide, Fludarabine, Mogamulizumab, Natural Killer Cell Therapy
Study Phase: Phase 1

Summary: This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body'...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
A Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Enrollment Status: Recruiting
Publish Date: February 05, 2026
Intervention Type: Drug, Biological
Study Phase: Phase 1

Background: Chemokine receptor 4 (CCR4) is a protein that is found on the surface of certain T-cell lymphoma cells and is common in mature T-cell cancers. White blood cells can be changed with molecules called anti-CCR4 to express a chimeric antigen receptors (CAR), which is a molecule that directs a white blood cell to attack other cells. The CAR in this study attacks the CCR4 protein found on your T-cell ly...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center